In the article, “Nevirapine once-daily: pharmacology, metabolic profile and efficacy data of the New extended release formulation (Expert Opinion on Drug Metabolism & Toxicology 2011;7(4):495-503), an error has been identified. On page 500, there is an error in the sentence ‘In addition, its use among naïve subjects is limited to males with < 450 CD4 and females with < 200, CD4, while patients will tend to start treatment sooner with higher CD4 cells.’ The correct sentence should be, ‘In addition, its use among naïve subjects is limited to males with < 400 CD4 and females with < 250, CD4, while patients will tend to start treatment sooner with higher CD4 cells’.
Informa Healthcare and the authors of this article would like to apologize for any confusion caused.